中国实验诊断学
中國實驗診斷學
중국실험진단학
CHINESE JOURNAL OF LABORATORY DIAGNOSIS
2014年
4期
586-588
,共3页
人乳头瘤病毒%尿液%筛查
人乳頭瘤病毒%尿液%篩查
인유두류병독%뇨액%사사
human papillomavirus%urine%screening
目的:检测尿液标本中人类乳头瘤病毒(HPV),并与宫颈以及外阴标本进行比较,探讨其与宫颈疾病的相关性,从而为宫颈癌的筛查提供参考。方法收集患者新鲜尿液以及外阴和宫颈分泌物,采用基于 PCR 的线性阵列基因分型技术检测 HPV。同时计算3种标本中 HPV 检出率的一致性,并与临床细胞与组织学分型做比较。结果致癌性 HPV 在尿液和宫颈样本的一致性是80%(112/140),尿液与外阴样本中的一致性为83.3%(110/132),外阴和宫颈样本中的一致性为90.9%(120/132)。尿液中致癌性 HPV 的敏感性和特异性分别为81.8%(95% CI=69.4-92.2)和51.1%(95% CI=35.6-68.4),宫颈标本中 HPV 敏感性和特异性分别为95.5%(95% CI=81.2-99.7)和40.4%(95% CI=24.7-56.2),外阴分泌物中 HPV 敏感性和特异性分别为95.2%(95% CI=80.5-99.5)和40.5%(95% CI=25.5-57.5)。结论尿液致癌性 HPV 检出率较低,但与临床细胞与组织学检查具有较好的一致性。因此还有待增加样本含量以进一步评价其在宫颈癌筛查中的作用。
目的:檢測尿液標本中人類乳頭瘤病毒(HPV),併與宮頸以及外陰標本進行比較,探討其與宮頸疾病的相關性,從而為宮頸癌的篩查提供參攷。方法收集患者新鮮尿液以及外陰和宮頸分泌物,採用基于 PCR 的線性陣列基因分型技術檢測 HPV。同時計算3種標本中 HPV 檢齣率的一緻性,併與臨床細胞與組織學分型做比較。結果緻癌性 HPV 在尿液和宮頸樣本的一緻性是80%(112/140),尿液與外陰樣本中的一緻性為83.3%(110/132),外陰和宮頸樣本中的一緻性為90.9%(120/132)。尿液中緻癌性 HPV 的敏感性和特異性分彆為81.8%(95% CI=69.4-92.2)和51.1%(95% CI=35.6-68.4),宮頸標本中 HPV 敏感性和特異性分彆為95.5%(95% CI=81.2-99.7)和40.4%(95% CI=24.7-56.2),外陰分泌物中 HPV 敏感性和特異性分彆為95.2%(95% CI=80.5-99.5)和40.5%(95% CI=25.5-57.5)。結論尿液緻癌性 HPV 檢齣率較低,但與臨床細胞與組織學檢查具有較好的一緻性。因此還有待增加樣本含量以進一步評價其在宮頸癌篩查中的作用。
목적:검측뇨액표본중인류유두류병독(HPV),병여궁경이급외음표본진행비교,탐토기여궁경질병적상관성,종이위궁경암적사사제공삼고。방법수집환자신선뇨액이급외음화궁경분비물,채용기우 PCR 적선성진렬기인분형기술검측 HPV。동시계산3충표본중 HPV 검출솔적일치성,병여림상세포여조직학분형주비교。결과치암성 HPV 재뇨액화궁경양본적일치성시80%(112/140),뇨액여외음양본중적일치성위83.3%(110/132),외음화궁경양본중적일치성위90.9%(120/132)。뇨액중치암성 HPV 적민감성화특이성분별위81.8%(95% CI=69.4-92.2)화51.1%(95% CI=35.6-68.4),궁경표본중 HPV 민감성화특이성분별위95.5%(95% CI=81.2-99.7)화40.4%(95% CI=24.7-56.2),외음분비물중 HPV 민감성화특이성분별위95.2%(95% CI=80.5-99.5)화40.5%(95% CI=25.5-57.5)。결론뇨액치암성 HPV 검출솔교저,단여림상세포여조직학검사구유교호적일치성。인차환유대증가양본함량이진일보평개기재궁경암사사중적작용。
Objective To investigate the urine-based sampling for (human papillomavirus,HPV)detection for cervi-cal cancer screening,data comparing HPV genotyping in urine versus those in cellular sampling of the cervix and vulva, and their correlation with rigorously-confirmed cervical disease.Methods The voided-urine and clinician collected vul-var and cervical samples were collected,HPV detection and genotyping were performed by a polymerase chain reaction-based linear array HPV genotyping test assay.The concordance for HPV detection between samples was analyzed,and the positivity rate across individual disease categories by cytology and histology results were also evaluated.Results The overall agreement of HPV carcinogenic was 80% in the urine and cervical samples,83.3% in urine and vulvar sam-ples,and 90.9% in vulvar and cervical samples.The corresponding sensitivity and specificity values for urine sampling were 81.8% (95% CI=69.4-92.2)and 51.1% (95% CI=35.6-68.4),and those for cervical sampling were 95.5%(95% CI=81.2-99.7)and 40.4% (95% CI=24.7-56.2),for vulvar were 95.2% (95% CI=80.5-99.5)and 40.5%(95% CI=25.5-57.5),respectively.Conclusion the relatively lower detection rates but comparable clinical perform-ance of urine-based HPV sampling underscores the need for larger studies to evaluate urine-based sampling for cervical cancer screening.